Last week in Warsaw, a meeting took place between the Center's management, Director Mykhailo Babenko and Deputy Director Yevheniia Tkachenko, and the president of one of the largest European institutions engaged in the assessment and tariff-setting of medical technologies – Doctor, Professor Roman Topór-Mądry.
The parties met to discuss current issues and prospects for the development of HTA in Ukraine.
During the event, representatives of the Polish Agency spoke about the HTA system in Poland, its legal regulation, structure and statutory tasks, areas of authority, role in the country's healthcare system, and decision-making algorithms.
“The meeting in Warsaw opened up to me genuine European prospects for the development of health technology assessment. While today in Ukraine HTA is carried out for medicinal products, and HTA for medical devices and hospital HTA are being actively developed, the areas of authority of the Polish Agency number about twenty. These include health technology assessment for medicinal products, dietary supplements, medical devices and services, issuing opinions on projects in the field of health care, clinical guidelines, reimbursement issues, pricing… All efforts are aimed at helping the state formulate a safe, effective, patient-centered and cost-effective health care policy. They are truly great people and are ready to share their experience, so our cooperation will continue,” – Mykhailo Babenko commented on the meeting in Warsaw.
Reference
The Agency for Health Technology Assessment and Tariff System of Poland was established in Poland in 2005. Currently, it has 5 branches throughout the country, employing 250 staff. Among its main powers and tasks are the following:
- conducting HTA of medicinal products, dietary supplements, medical devices and services;
- emergency access to medical technologies;
- medicinal products for people from 75 years of age;
- providing opinions on draft healthcare programs (mandatory for implementation);
- providing recommendations on healthcare programs;
- service pricing;
- changes in the structure of service provision;
- providing opinions on clinical guidelines;
- analyses and studies in the field of healthcare, pricing, and benefits;
- reimbursement;
- standardization of cost accounting;
- sickness fund: innovative technologies;
- COVID-19;
- national cancer control strategy;
- mapping of needs in the healthcare sector;
- plan on rare diseases;
- minimum wage;
- others.
